TB-500

TB-500 is a synthetic 7-amino-acid fragment (Ac-LKKTETQ) corresponding to a small piece of thymosin beta-4, a natural 43-amino-acid protein with a real clinical development history. TB-500 itself has never been the subject of a single published human study, has no registered human trial, and the one time it was directly tested in a wound-healing assay, it didn’t work, only a smaller breakdown product showed any activity. Much of what’s said about TB-500 online is actually evidence about thymosin beta-4, a different molecule with a different safety and efficacy record.

Ask about TB-500 / thymosin beta-4

Research snapshot

CategoryCurrent information
Peptide categorySynthetic fragment of thymosin beta-4 (a natural 43-amino-acid protein)
Primary research interestTissue, tendon, and wound healing (mostly inferred from the parent protein, not TB-500 itself)
Highest available evidenceTier 4: laboratory / animal only, and largely for the parent protein rather than TB-500 itself
Human research availableNo: zero published human studies or registered trials of TB-500 itself
Development statusUnapproved research chemical; never entered a registered drug pipeline under this name
Regulatory statusNot approved as a drug anywhere; banned in sport under the parent-protein class; named in a draft HHS 503A enforcement-discretion policy published 30 Oct 2026 (not approval)

Technical identity

Technical propertyInformation
Primary nameTB-500
Alternative namesThymosin beta-4 fragment 17–23, Ac-LKKTETQ
Peptide sequenceAc-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ), residues 17–23 of thymosin beta-4
Amino-acid length7 (about 18% of the parent protein by mass)
Molecular formulaNot independently verified in this review
Molecular weight≈889 Da (fragment) vs. 4,921 Da for full thymosin beta-4
CAS Registry Number885340-08-9
PubChem CIDNot confirmed from independent sources
Peptide classActin-binding-domain fragment of thymosin beta-4
Primary biological targetActin-binding motif; the fragment’s own activity in a wound-healing assay was negative, only a smaller breakdown product showed activity
Developer / originatorNot a registered pharmaceutical candidate; derived academically from thymosin beta-4 research
Development statusUnapproved research chemical / vendor product; the parent protein (as timbetasin) has clinical history, TB-500 itself does not

What it is

TB-500 is a synthetic chain of seven amino acids with an acetyl group on one end, Ac-LKKTETQ. It corresponds to residues 17 to 23 of thymosin beta-4, a natural protein of 43 amino acids, so about 18 percent of it by mass, 889 daltons against 4,921.

Thymosin beta-4 has a drug name, timbetasin, development codes, a decade of registered trials and published human safety data. TB-500 has none of those. The evidence for one does not transfer to the other.

FDA says so explicitly. Acetylation irreversibly alters a peptide charge, hydrophobicity and size, so in its words the profile of the non-acetylated heptapeptide cannot be extrapolated to TB-500. That matters, because most of the fragment research used the non-acetylated version, a third distinct molecule.

FDA also found TB-500 not physically or chemically well characterised, citing naming that does not follow nomenclature standards and missing impurity data in both the literature and the certificates of analysis it reviewed. Tests for impurities, aggregates, microbiological quality and endotoxin are not in the public domain.

The substitution problem

The confusion is not confined to marketing. It is in the peer-reviewed literature.

  • A 2026 review in a pain journal lists thymosin beta-4 and thymosin beta-500 as separate entities, inventing an expansion of the acronym. The 500 is a product number and there is no such peptide.
  • A 2026 scoping review in a sports medicine journal treats the pair as a single search unit, which pools evidence for the two molecules into one bucket.
  • A 2026 rat tendon study titles its intervention synthetic thymosin beta-4 (TB-500), treating the seven-mer as though it were the 43-mer.
  • A 2025 materials science paper applies the name TB500 to a hydrogel containing the non-acetylated sequence, which is the third molecule again.
  • A major research chemical catalogue lists the correct CAS number under a title calling it a thymosin beta-4 synthetic molecule, while its own datasheet gives the seven amino acid sequence. The title asserts what the datasheet denies.
  • Retail listings exist advertising TB-500 while describing the contents as full-length 43 amino acids, which is the substitution running in the opposite direction.

One 2026 review in Sports Medicine handles it correctly, listing thymosin beta-4 and TB-500 as two distinct entries. That is the minority practice.

How it works

Thymosin beta-4 binds monomeric actin one to one and buffers it. That is established for the parent protein. Whether TB-500 does it is a different question, and the structural literature suggests not.

LKKTET is the contact motif, but the function that prevents polymerisation needs the segment upstream of it, and a separate study found that extending the protein first helix over the LKK segment abolishes activity. TB-500 has no first helix, and no published paper measures actin binding for Ac-LKKTETQ.

The benefits map to other parts of the protein

The canonical map of thymosin beta-4 assigns its anti-inflammatory and anti-fibrotic activity to residues 1 to 4, and its cell survival activity to residues 1 to 15. TB-500 contains neither. A domain-mapping study across seventeen combinations in mice and pigs found the cardiac benefit belongs to residues 40 to 43, not 17 to 23. No preclinical cardiac study of TB-500 exists, and the mapping contradicts the cardiac claims attached to it.

One mechanism where the fragment matches the parent, and it is not a repair mechanism

Peptides corresponding to residues 17 to 23 stimulated mast cell mediator release at or above the level of native thymosin beta-4, in mouse and human cells. That is histamine and tryptase release, not repair, and it is the only mechanism where the fragment matches the full protein.

Potential benefits and research applications

Tissue and tendon repair

This is the claim driving nearly all real-world interest in TB-500, and it rests on a genuinely thin and mostly misattributed foundation. The entire preclinical basis for TB-500 as a marketed product traces to one sentence in a 2003 paper: in aged mice, a synthetic 7-amino-acid actin-binding peptide promoted wound repair comparably to the full parent protein. That peptide was not acetylated, meaning it was not TB-500. The one time TB-500 itself was directly tested in a wound-healing assay, it produced no effect at 50 mcg/mL in scratch-wound fibroblast cultures; only a smaller breakdown product (Ac-LKKTE, missing one residue) showed activity, leading the study’s own authors to conclude that any previously reported activity may belong to a metabolite rather than to TB-500 itself. Evidence tier: one negative laboratory study specific to TB-500; the positive foundational result used a different, non-acetylated molecule. Has not been shown effective in the one study that tested the actual marketed compound; the claim rests substantially on evidence for a related-but-distinct molecule.

Musculoskeletal and tendon injury

In July 2026, an independent Turkish group tested TB-500 directly in a rat Achilles tendon transection model, 32 animals across 4 groups, including a BPC-157 arm and a combination arm. TB-500 reached statistical significance on maximum load to failure and total histological (Bonar) score; BPC-157, tested in the same experiment, did not. Evidence tier: single independent animal study, the strongest in vivo evidence for TB-500 specifically that exists, with real limits (8 animals per group, one species, one model, intraperitoneal route rather than the subcutaneous route people actually use, four weeks duration). The combination arm did not outperform TB-500 alone, which is the entire in vivo evidence base for the “Wolverine” blend. Has been shown to improve tendon-healing measures in this one rat study; has not been tested in any large-animal model, any muscle or ligament injury model, or any human study of any kind.

Cardiac repair (contradicted by domain mapping)

Frequently claimed for TB-500 by association with thymosin beta-4’s cardiac research. The domain-mapping evidence directly contradicts this, the cardiac-relevant portion of the parent protein is a different region (residues 40-43) that TB-500 doesn’t contain. Evidence tier: contradicted by the available domain-mapping data. Has not been established, and the mechanistic evidence available argues against extrapolating thymosin beta-4’s cardiac research to TB-500.

Research evidence

Human evidence for TB-500: none

FDA, verbatim: the nomination did not include, and FDA did not find any information in the medical literature where TB-500 was administered to patients to treat any disease or condition. It also identified no human study of its pharmacokinetics or pharmacodynamics by any route.

An independent search confirms it. The correct statement for this compound is no human studies, not limited human studies.

Registered trials of TB-500: zero, and one trap

There are no registered interventional trials of TB-500 in humans. There are twenty registered trials of thymosin beta-4, which is a different molecule.

One record looks like an exception and is not. A ClinicalTrials.gov entry exists for a phase 1 and 2 study of TB-500 in atherosclerotic cardiovascular disease, listed as recruiting. Its own summary begins by stating that it is a fictional study and an example of a ClinicalTrials.gov-style record. It is a template, and exactly the kind of artefact that gets screenshotted as proof TB-500 is in trials.

The thymosin beta-4 human record, reported accurately

The parent protein has a real programme and it deserves an honest summary, because it is the thing whose credibility TB-500 borrows.

A phase 1 intravenous study in 40 healthy volunteers found no dose-limiting toxicity from 42 to 1,260 mg. A separate phase 1 in China used 0.05 to 25 micrograms per kilogram, roughly 3.5 micrograms to 1.75 mg for an adult, also well tolerated. Four orders of magnitude apart, both declared safe, so there is no reconciled human dose even for the parent protein.

On efficacy: one small phase 2 in severe dry eye, nine patients, was positive. A three-trial phase 3 dry eye programme, the last enrolling 700 people, missed its primary outcomes. A phase 3 in neurotrophic keratopathy was terminated at 18 enrolled, and two phase 2 wound trials were terminated. The injectable programme went on clinical hold in 2011 over manufacturing compliance, not safety, and never restarted. No approval anywhere.

Preclinical evidence, and what the foundation actually is

The entire preclinical basis for the TB-500 marketplace rests on one sentence in a 2003 paper: in aged mice, the actin-binding domain as a seven amino acid synthetic peptide promoted repair comparably to the parent molecule. A real result. The peptide was not acetylated, so it was not TB-500.

The one time TB-500 itself was tested for wound healing, it did not work. In scratch-wound fibroblast cultures, TB-500 free base at 50 micrograms per millilitre induced no healing. Of the parent and its metabolites, only Ac-LKKTE, a five amino acid breakdown product, showed activity. The authors concluded the previously reported activity may be due to the metabolite rather than the parent. FDA cites the same study.

That leaves open a first-order question: the marketed molecule may be a prodrug for something else, or it may be inert.

The one in vivo result that is genuinely TB-500

In July 2026 a Turkish group tested TB-500 at 60 micrograms per kilogram per day intraperitoneally in a rat Achilles transection model, 32 animals in four groups, alongside BPC-157 and a combination arm. TB-500 reached significance on load to failure and total Bonar score. BPC-157 did not.

That is the strongest in vivo evidence for TB-500 there is, with its limits: eight animals per group, one model, one species, intraperitoneal rather than the route people use, four weeks. The combination arm did not beat TB-500 alone, and that is the entire in vivo evidence base for the Wolverine blend.

Beyond that, no TB-500 study exists in any large-animal musculoskeletal model, or in any muscle injury, ligament or cartilage model.

Safety

The absences here are not gaps in an otherwise complete picture. They are the picture.

FDA found no nonclinical toxicity study of TB-500 of any kind. No no-effect level, no repeat-dose toxicity, no genotoxicity, no reproductive toxicity, no carcinogenicity. Also no pharmacokinetic study by the proposed route, and no in vivo work assessing whether it promotes wound healing at all.

There is no dose-response curve for TB-500 in any species for any endpoint. The two documented in vivo exposures are single point doses, and the longest exposure in any organism is four weeks.

Immunogenicity is FDA primary stated concern and has never been assessed in a human. The agency noted the proposed intramuscular and subcutaneous routes may pose significant risk, amplified by aggregation and peptide impurities, and that the nomination included no study assessing it.

One risk framing worth stating plainly. Thymosin beta-4 is overexpressed across a range of cancers and has been proposed as a knockdown target rather than something to supply, with RNA interference against it reducing tumour growth in mice. No TB-500 oncology data exists either way.

A vial may not contain the peptide at all

This is documented rather than suspected. The Racing Medication and Testing Consortium tested products marketed as TB-500 and reported that many contain no thymosin beta-4 or any peptide derived from it, most containing no proteins, peptides or amino acids at all. A French racing laboratory independently reported products online claiming to contain either the acetylated fragment or the full protein, the same substitution seen from the analytical side.

No systematic purity survey of the current market has been published, so the proportions are unknown. A given vial may hold the fragment, the full protein, a different peptide, or nothing peptidic.

Regulatory status

TB-500 is not an approved drug for any indication anywhere, and neither is thymosin beta-4. Its entry in the FDA substance registry is identification, not approval.

FDA proposed not adding TB-500 free base or acetate to the 503A compounding list on four grounds: inadequate characterisation, no historical compounding use, no evidence of effectiveness, unknown human safety risk. On historical use the finding was categorical, that no studies were found using TB-500 as a compounded product and no outsourcing facility has reported compounding it. It sits on the Category 2 page among substances nominated but withdrawn.

On 23 July 2026 the Pharmacy Compounding Advisory Committee voted eight to six with one abstention to recommend adding TB-500, against FDA staff, in a single grouped vote that also covered BPC-157 and KPV (AJMC). The tally comes from trade press, and the official minutes had not been checked. The vote is advisory, and a proposed rule, public comment and a final rule would have to come first. As of mid-August 2026 reporting, FDA had not acted on the vote. News reports on 7 to 8 October 2026 said the administration was drafting plans for temporary sales of some unapproved peptides without naming them. HHS then published the notice summarized below on 30 October 2026.

On 28 October 2026 HHS announced a draft enforcement discretion policy for compounding certain peptides under section 503A. It was published in the Federal Register on 30 October 2026 (91 FR 68526, docket HHS-OASH-2026-0496). TB-500 is one of six peptides named, listed as TB-500 acetate (Ac-LKKTETQ), with subcutaneous or intramuscular use as the routes in its Appendix B. HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians compounding it under 503A if conditions are met. These include a patient-specific prescription, one active ingredient per product, an ingredient from an FDA-registered CGMP manufacturer with a certificate of analysis showing the facility location, adverse event reporting, and the label “This is a compounded drug product. Not for resale.” It is a draft and is not binding on HHS or the public. It is not an FDA approval, it does not add TB-500 to the 503A bulks list, and it is not a rule. It does not bind state boards of pharmacy. HHS says it stays in place until each peptide is addressed in a final rule, and it can be withdrawn. It does not cover 503B outsourcing facilities. Comments close 13 November 2026. This entry found no published human studies or registered trials of TB-500 itself, and the notice does not change that: the evidence tier on this page is unchanged. The full analysis of the HHS policy covers all six peptides. For a plain-language report on the same policy, see The Weight Loss Atlas report on the HHS enforcement discretion policy, and for the dated sequence of decisions, its peptide policy tracker.

TB-500 is also sold inside multi-peptide mixes, which is where many people first meet the name. Wolverine pairs it with BPC-157, GLOW adds GHK-Cu, and KLOW adds KPV as well. No study has tested any of those combinations, and in the commonly stated vial math the TB-500 share per dose is much lower than the amounts that circulate for TB-500 alone. Each blend page works through the arithmetic.

The anti-doping language is cleaner than the scientific literature, unusually. The WADA prohibited list, section S2.3, reads: thymosin-beta-4 and its derivatives e.g. TB-500. By naming the parent and adding its derivatives it sidesteps the identity problem, so the fragment is caught whether or not it is the same thing. Prohibited at all times, in and out of competition. A Canadian volleyball athlete got a four-year sanction in 2024 for BPC-157 and TB-500.

Horse racing is the best-evidenced strand, because TB-500 was a veterinary product first and racing laboratories built detection methods years earlier. The Racing Medication and Testing Consortium recommends the most severe penalty category, notes FDA has not assessed the peptide in the horse, and records metabolites detectable for roughly ten hours after injection, which makes it prohibited but hard to catch on race day.

Handling and identity

The identifiers for the parent protein conflict: the FDA registry gives one CAS number and chemical catalogues widely give another. For TB-500 the CAS number is concordant. No PubChem identifier for it could be confirmed from two sources, so none is published here.

TB-500 is cleaved rapidly. In rats the two-residue Ac-LK was the main metabolite in the first six hours and the three-residue Ac-LKK stayed detectable to 72 hours. In vitro, peptides of this kind degrade at all bonds regardless of protective modifications. Any circulating half-life figure has no human source.

Other fragment names circulate and none is interchangeable with TB-500: Ac-SDKP is residues 1 to 4, AGES is 40 to 43, plain LKKTETQ is the non-acetylated 17 to 23. Retail listings exist describing TB-500 as the fragment 1 to 4, which is the wrong fragment entirely.

Frequently asked questions

What is TB-500?

A synthetic 7-amino-acid fragment (Ac-LKKTETQ) of a natural 43-amino-acid protein called thymosin beta-4.

Is TB-500 the same as thymosin beta-4?

No, and this is the single most important thing to understand about this compound. Thymosin beta-4 has a real drug-development history with human trials; TB-500, the small fragment, has never been tested in a human at all.

Has TB-500 been studied in humans?

No. Zero published or registered human trials exist. A circulated ClinicalTrials.gov record for a “TB-500 trial” is a fictional template record, not a real study.

Reported useRouteAmount reportedFrequencyDurationEvidence category
Human researchNot reportedNot establishedNot reportedNot reportedNo published human trial or registered study of TB-500 itself
Animal researchIntraperitoneal (rat); single dose (racehorse)60 mcg/kg/day (rat tendon study); a single 10 mg dose (2 racehorses, drug-detection study)Daily (rat study)Study-specificTwo animal data points specific to TB-500 itself, not a dosing program
General use (as commonly circulated online)Subcutaneous2–10 mg per weekLoading, then maintenance patternVendor/community-definedCommunity / vendor reported: one widely circulated protocol’s cited sources were checked and found unrelated to TB-500

What dosage has been studied?

No human dose exists. The only animal dose specific to TB-500 itself is 60 mcg/kg/day intraperitoneally in one rat tendon study, and a single 10 mg dose given to two racehorses in a drug-detection study.

What dosage commonly circulates online?

Most commonly 2 to 10 mg per week, subcutaneously, in a loading-then-maintenance pattern. One widely circulated protocol page’s cited sources were checked and found to have nothing to do with TB-500, one was about leafhopper feeding behavior.

Does TB-500 heal tendons?

The one independent rat study testing TB-500 itself found a positive effect on tendon-healing measures. The foundational claim that built TB-500’s reputation, however, used a different, non-acetylated molecule, and the one direct wound-healing test of TB-500 itself found it inactive.

Is TB-500 banned in sports?

Yes, explicitly. WADA’s Prohibited List names “thymosin-beta-4 and its derivatives, e.g. TB-500” directly, prohibited at all times.

What side effects have been reported?

None have been formally studied in any species, no toxicology data of any kind exists for TB-500. Separately, testing has found that many products sold as TB-500 contain no TB-500, or no peptide at all.

Is it legal to buy or use?

Not FDA-approved anywhere. Currently under review, not approval, for pharmacy-compounding eligibility, over the objection of FDA’s own reviewers.

What remains unknown?

Almost everything about how TB-500 itself behaves: whether it’s even the active molecule (the one efficacy test found it inactive), any human pharmacokinetics, any toxicology, and, most practically, what’s actually in a given commercially sold vial.

Bottom line

TB-500’s entire commercial reputation rests on evidence for a different molecule. The parent protein, thymosin beta-4, has a real (if ultimately discontinued) clinical development history; TB-500, the small fragment actually sold, has never been given to a human being in any published study, and the one time it was directly tested for the effect it’s sold for, it didn’t work. What’s genuinely published: one solid independent rat study showing a real effect on tendon-healing measures, and a body of research on the parent protein that mostly doesn’t transfer to the fragment. What’s merely reported online: the entire dosage picture in circulation, built on numbers that trace either to a different molecule’s human trial or to a veterinary vial size, with at least one widely circulated protocol page’s citations found to be about entirely unrelated topics. TB-500 is not FDA-approved, has no human safety data of any kind, is explicitly banned in competitive sport, and testing by racing authorities has found that a meaningful share of products sold under this name may not contain it at all.

For the BPC-157 side of the pairing, including how its amounts compare with TB-500 figures, see the BPC-157 dosage guide.

Every TB-500 and thymosin beta-4 amount that has been studied or repeated, with sources, is in the TB-500 dosage guide.

Its compounding category and the 2026 committee outcome are tracked in FDA peptide status.

What circulates E5

Figures reported online. Not dosing, not verified, not endorsed.
Reported useRouteAmount reportedFrequencyReported length
Injury, loading phaseSubcutaneous2 to 2.5 mg per injectionTwice weekly4 to 6 weeks
Injury, aggressive loadingSubcutaneous5 to 10 mg per week2 to 3 injections4 weeks
MaintenanceSubcutaneous2 to 2.5 mg per weekOne or two injections4 to 6 weeks
Wellness or anti-ageing framingSubcutaneous2 mgEvery two weeksNot specified
As part of the Wolverine blendSubcutaneous2 to 5 mgOnce or twice weekly4 to 12 weeks

Circulating TB-500 protocols are unusually uniform in shape, a loading phase followed by maintenance, and they converge on two overlapping numeric bands. Route is essentially unanimous: subcutaneous injection from a 5 mg or 10 mg vial.

Following where the figures come from produced the starkest result of any compound surveyed for this site. Several pages carrying complete numeric loading and maintenance schedules supplied no references at all. Two of those instead carried a clinician name as a reviewed-by credential, which is not a source for a number.

One widely circulated dosing page did supply exactly four PubMed links as its evidence base. All four were retrieved. None concerns TB-500, thymosin beta-4, peptides, tissue repair, or human dosing of anything. They are a study of stylet feeding behaviour in the tea green leafhopper, a review of melatonin and adolescent idiopathic scoliosis, a one-page news commentary on a heat-shock protein structure, and a review of porcine parvovirus. The PubMed identifiers are 22750027, 17408483, 12032550 and 31822635, so anyone can check this. The citations are decorative.

Where the magnitude does trace to something real, it traces to the wrong molecule. The one human trial with milligram-scale dosing in this family used thymosin beta-4 intravenously at 42 to 1,260 mg daily in 40 volunteers with no dose-limiting toxicity. Circulating TB-500 figures of 2 to 10 mg per week sit comfortably inside that window by absolute mass, which is exactly why a milligram dose feels safe to anyone who has seen that trial. Different molecule, different route, different setting, different duration.

The recurring 10 mg figure has a second and more likely origin, and it is not human. A single 10 mg subcutaneous dose was given to two thoroughbred geldings in a racing laboratory detection study, and 10 mg is the standard marketed vial size for the equine product. The most repeated human loading number is equally well explained as a veterinary vial size carried across species without adjustment.

For the Wolverine blend specifically: no clinical trial of any BPC-157 and TB-500 combination exists, and no registered trial of it was found. The one preclinical combination study is the rat Achilles model, in which the combination did not outperform TB-500 alone on the measures that reached significance.

Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.

Sources

  1. US Food and Drug Administration. FDA evaluation of TB-500-related bulk drug substances. Briefing document dated 15 May 2026. FDA media 193349
  2. Esposito S, et al. Characterisation of the peptide in a TB-500 formulation by HPLC and high-resolution mass spectrometry, confirmed against synthesised Ac-LKKTETQ. Drug Test Anal. 2012. PMID 22962027
  3. Rahaman KA, et al. Metabolism of TB-500 and wound-healing activity of its metabolites. J Chromatogr B. 2024. TB-500 itself was inactive in the scratch-wound assay; only Ac-LKKTE showed activity. PMID 38382158
  4. Philp D, et al. Thymosin beta-4 and a synthetic seven amino acid actin-binding domain promote dermal wound repair in diabetic and aged mice. 2003. Note: the fragment used was not acetylated. PMID 12581423
  5. Vancompernolle K, et al. The interfaces of actin and thymosin beta-4 peptides: LKKTET is the contact motif but the inhibitory function requires the upstream segment. EMBO J. 1992. PMID 1464307
  6. Simenel C, et al. Structural requirements for thymosin beta-4 activity: extension of helix I over the LKK segment abolishes activity. Eur J Biochem. 2000. PMID 10848969
  7. Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta-4 defined by active sites in short peptide sequences. FASEB J. 2010. PMID 20179146
  8. Hinkel R, et al. Thymosin beta-4 domain mapping in mice and pigs: the C-terminal AGES tetrapeptide, not residues 17 to 23, carries the cardiac effect. J Mol Cell Cardiol. 2015. PMID 26255251
  9. Wyczolkowska J, et al. Thymosin beta-4 and its fragments 16-38 and 17-23 stimulate mast cell mediator release at levels equal to or higher than native thymosin beta-4. Peptides. 2007. PMID 17289217
  10. Shah R, Reyes-Gordillo K, Rojkind M. The thymosin beta-4 17-23 peptide inhibits PDGF-BB driven fibrogenic signalling in hepatic stellate cells. Expert Opin Biol Ther. 2018. Non-acetylated peptide. PMID 30063851
  11. Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta-4 in healthy volunteers. Ann N Y Acad Sci. 2010. Doses 42 to 1,260 mg. PMID 20536472
  12. Phase 1a and 1b studies of recombinant human thymosin beta-4 in healthy Chinese volunteers. J Cell Mol Med. 2021. Doses 0.05 to 25 micrograms per kilogram. PMID 34346165
  13. Sosne G, et al. Thymosin beta-4 ophthalmic solution for severe dry eye: a randomized, double-masked, vehicle-controlled phase 2 clinical trial. Cornea. 2015. PMID 25826322
  14. Comparison of BPC-157 and TB-500 on Achilles tendon healing in a rat model. Jt Dis Relat Surg. 2026. PMID 42542926
  15. Ho ENM, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta-4, in equine urine and plasma. J Chromatogr A. 2012. Single 10 mg subcutaneous dose in two geldings. PMID 23084823
  16. Chao TF, et al. Thymosin beta-4 knockdown suppresses colorectal tumour growth in nude mice. Cancer Gene Ther. 2014. PMID 25124811
  17. Delcourt V, et al. Endogenous thymosin beta-4 in racing horse blood and detection of a synthesis impurity after administration. Drug Test Anal. 2024. PMID 39314109
  18. Racing Medication and Testing Consortium. Thymosin beta-4 bulletin. Reports that many products marketed as TB-500 contain no thymosin beta-4 or derived peptide, most containing no proteins, peptides or amino acids. RMTC bulletin
  19. Lists "Thymosin-β4 and its derivatives e.g. TB-500" under S2.3, Growth Factors and Growth Factor Modulators, a non-specified substance class prohibited at all times, in and out of competition. WADA Prohibited List
  20. US Food and Drug Administration. Ipamorelin acetate, 503B, listed 29 September 2023, citing immunogenicity risk and serious adverse events including death reported in the literature after intravenous administration. FDA Category 2
  21. US Food and Drug Administration. Briefing document for the Pharmacy Compounding Advisory Committee: TB-500 (free base and acetate). July 2026. FDA media 193349
  22. FDA Panel Backs 6 Peptides for Compounding. American Journal of Managed Care. July 2026. AJMC

Live registry status

These are the registered trials this page cites, pulled from ClinicalTrials.gov and refreshed automatically. Status and dates are what the registry currently shows. Listing a trial here does not mean it produced a positive result.

TrialPhaseStatusSponsorEnrolledPrimary completionRegistry updated
A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers
NCT04555824
Phase 1CompletedBeijing Northland Biotech. Co., Ltd.54Feb 20, 2018Sep 29, 2020
A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteers
NCT04555850
Phase 1CompletedBeijing Northland Biotech. Co., Ltd.30Feb 18, 2019Sep 29, 2020

Open these in the trial tracker

Share thisFacebookXEmail